摘要
目的 探究非麦角类多巴胺受体(Dexpramipexole dihydrochloride,DR)激动剂联合筋膜松解术对帕金森病(Parkinson’s disease,PD)患者对血清胱抑素C(CysC)、同型半胱氨酸(Hcy)水平的影响。方法 选取2017年10月~2019年12月治疗的60例帕金森病患者,按照随机数表法分成研究组和对照组,每组30例,两组患者均给予筋膜松解术治疗,研究组在以上基础上给予DR激动剂治疗,两组患者均治疗12周,对比两组患者干预前后的血清CysC及Hcy水平,采用帕金森病病统一评分量表(UPDRS)对两组干预前后的评分对比及两组患者不良反应发生率。结果干预前两组血清CysC及Hcy水平差异无统计学意义(P> 0.05),干预后两组血清CysC及Hcy水平下降,同时研究组患者血清因子水平低于对照组,差异有统计学意义(P <0.05);干预前两组UPDRS评分差异无统计学意义(P> 0.05),干预后两组血清UPDRS评分下降,同时研究组UPDRS评分水平低于对照组(P <0.05);两组治疗前剂末现象、开关现象、异动症临床症状发生率差异无统计学意义(P> 0.05),治疗后研究组患者以上症状发生率低于对照组(P <0.05);研究组患者不良反应5例,发生率为16.7%,对照组患者不良反应7例,发生率为23.3%,差异无统计学意义(P> 0.05)。结论 DR激动剂联合筋膜松解术能够显著降低PD患者血清CysC、Hcy水平,同时改善患者临床症状,且具有较高的安全性。
Objective To explore the effect of non ergot dopamine receptor(DR) agonist combined with fasciolysis on serum cystatin C(Cys C) and homocysteine(Hcy) levels in patients with Parkinson’s disease(PD).Methods 60 patients with Parkinson’s disease treated in our hospital from October 2017 to December 2019were selected,according to the random number table method,divided to the study group and the control group,30 cases in each group.The two groups were given fasciolysis treatment,and the study group was given Dr agonist treatment on the basis of the above.The two groups were treated for 12 weeks.The serum CysC and Hcy levels of the two groups before and after intervention were compared,and the Unified Parkinson’s disease assessment was used UPDRS was used to compare the scores of the two groups before and after the intervention and the incidence of adverse reactions.Results The serum levels of CysC and Hcy in the two groups before the intervention were no significantly different(P > 0.05).After the intervention,the serum levels of CysC and Hcy in the two groups decreased,and the serum levels of factors in the study group were lower than those in the control group,there was significant difference(P 0.05).After the intervention,the UPDRS scores in the two groups decreased,and the UPDRS scores in the study group were lower than those in the control group(P 0.05).The incidence of the above symptoms in the study group was lower than that in the controlgroup(P 0.05).Conclusion DR combined with fasciolysis can significantly reduce the serum CysC and Hcy levels of PD patients,improve the clinical symptoms of patients,and has high safety.
作者
李金芝
王秦川
赵敏
LI Jin-Zhi;WANG Qin-Chuan;ZHAO Min(Department of Neurology,Aksu Municipal People's Hospital,Aksu 843000,China)
出处
《中国处方药》
2022年第6期50-52,共3页
Journal of China Prescription Drug
